Presumptive identification of  species other than , , and  with the chromogenic medium CHROMagar Candida by unknown
BioMed Central
Annals of Clinical Microbiology and 
Antimicrobials
ssOpen AcceResearch
Presumptive identification of Candida species other than C. albicans, 
C. krusei, and C. tropicalis with the chromogenic medium 
CHROMagar Candida
Duane R Hospenthal*1, Miriam L Beckius2, Karon L Floyd2, 
Lynn L Horvath1,2 and Clinton K Murray1
Address: 1Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas, USA and 2Department of Clinical Investigation, 
Brooke Army Medical Center, Fort Sam Houston, Texas, USA
Email: Duane R Hospenthal* - duane.hospenthal@amedd.army.mil; Miriam L Beckius - miriam.beckius@amedd.army.mil; 
Karon L Floyd - karon.floyd@amedd.army.mil; Lynn L Horvath - lynn.horvath@amedd.army.mil; 
Clinton K Murray - clinton.murray@amedd.army.mil
* Corresponding author    
Abstract
Background: CHROMagar Candida (CaC) is increasingly being reported as a medium used to
differentiate Candida albicans from non-albicans Candida (NAC) species. Rapid identification of NAC
can assist the clinician in selecting appropriate antifungal therapy. CaC is a differential chromogenic
medium designed to identify C. albicans, C. krusei, and C. tropicalis based on colony color and
morphology. Some reports have proposed that CaC can also reliably identify C. dubliniensis and C.
glabrata.
Methods: We evaluated the usefulness of CaC in the identification of C. dubliniensis, C. famata, C.
firmetaria, C. glabrata, C. guilliermondii, C. inconspicua, C. kefyr, C. lipolytica, C. lusitaniae, C. norvegensis,
C. parapsilosis, and C. rugosa.
Results: Most NAC produced colonies that were shades of pink, lavender, or ivory. Several
isolates of C. firmetaria and all C. inconspicua produced colonies difficult to differentiate from C.
krusei. Most C. rugosa isolates produced unique colonies with morphology like C. krusei except in a
light blue-green color. C. glabrata isolates produced small dark violet colonies that could be
differentiated from the pink and lavender colors produced by other species. All seventeen isolates
of C. dubliniensis produced green colonies similar to those produced by C. albicans.
Conclusion: C. glabrata and C. rugosa appear distinguishable from other species using CaC. Some
NAC, including C. firmetaria and C. inconspicua, could be confused with C. krusei using this medium.
Background
Candida albicans once accounted for most serious nosoco-
mial candidal infections. Over the last decade Candida
infections, specifically candidemia, due to C. albicans have
declined [1]. Other non-albicans Candida species (NAC)
are now responsible for about half of candidemias and
other deep Candida infections [2-4]. Most NAC infections
are caused by C. glabrata, C. parapsilosis, or C. tropicalis,
although in total over a dozen NAC have been reported to
cause candidemia and other invasive infections [5-8]. In
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amphotericin B, clinicians now must chose from azoles
with differing spectrums of activity (fluconazole, itracona-
zole, and voriconazole) and echinocandin antifungal
agents. In vitro testing has revealed that there are clear dif-
ferences among the various NAC in their susceptibility to
specific drugs. Rapid, reliable identification to species is
now needed more than ever for clinicians to make treat-
ment choices.
Identification of yeast pathogens by traditional methods
requires several days and specific mycological media.
Chromogenic media contain chromogenic substrates
which react with enzymes secreted by the target microor-
ganisms to yield colonies of varying colors. CHROMagar
Candida (CaC) is one such medium that, per its manufac-
turer (CHROMagar Microbiology, Paris, France, http://
www.chromagar.com), can identify three candidal yeasts,
C. albicans (green colonies), C. tropicalis (steel blue colo-
nies), and C. krusei (fuzzy, rose colored colonies) after 48
hours of incubation at 30–37°C. Independent groups
have reported success with CaC in differentiating C. dub-
liniensis from C. albicans [9,10]. Investigators have also
reported the ability to distinguish C. glabrata from other
species [11-14], although this has been contested by other
authors [15-17].
We studied the appearance of 180 isolates of 12 Candida
species on CaC to determine whether these more rare spe-
cies could be reproducibly distinguished from each other
with this medium.
Methods
Clinical yeast isolates were employed for all testing, pre-
dominately from our facility. Additional isolates were
provided by the Fungus Testing Laboratory, University of
Texas Health Science Center at San Antonio, Texas. Yeasts
tested included C. dubliniensis (17 isolates), C. famata (11
isolates), C. firmetaria (12 isolates), C. glabrata (38 iso-
lates), C. guilliermondii (10 isolates), C. inconspicua (6 iso-
lates), C. kefyr (9 isolates), C. lipolytica (10 isolates), C.
lusitaniae (15 isolates), C. norvegensis (3 isolates), C. parap-
silosis (34 isolates), and C. rugosa (15 isolates). Five iso-
lates each of C. albicans, C. krusei, and C. tropicalis were
used as controls. All isolates were identified by standard
clinical practices as previously described [18].
Inocula from clinical isolates stored at -70°C were trans-
ferred into yeast extract peptone (YEP) broth (Bacto Pep-
tone, BD, Sparks, MD) and incubated at 30°C in a rocking
incubator for up to 96 hours. Recovered yeasts were then
streaked for isolation onto Sabouraud dextrose agar
(SDA) plates (BD, Sparks, MD) and incubated at 30°C for
Table 1: The appearance of Candida species grown on CHROMagar Candida.
Colony characteristics
Species Isolates (no.) Color Morphology
C. dubliniensis 17 Green --a
C. famata 11 Pink to lavender --
C. firmetaria 12 Pink to lavender, pale border Some flat, rough; others waxyb
C. glabrata 38 Dark violetc Small to medium, smooth, convex, creamy
C. guilliermondii 10 Pink to lavender --
C. inconspicua 6 Pink to lavender, pale borders Flat, roughd
C. kefyr 9 Pink to lavender, often with 
darkened centers
Large, rough
C. lipolytica 10 Ivory to pink Large, flat, rough, wrinkledb
C. lusitaniae 15 Pink to lavender Some waxy
C. norvegensis 3 Ivory to pink Large, roughb
C. parapsilosis 34 Ivory to pink to lavender Small to medium, smooth to wrinkled
C. rugosa 15 Light blue-green, pale bordere Medium to large, flat
C. albicans 5 Green --
C. krusei 5 Pink, pale borders Medium to large, flat, rough
C. tropicalis 5 Steel blue, purple diffusion --
amorphology if not noted – medium size, smooth, convex, creamy
bsome isolates produce colonies indistinguishable from C. krusei
cdark pink colonies at 24 hours, darkening with time; colonies commonly had thin pale borders and produced pigment which diffused into medium
dall isolates indistinguishable from C. krusei
eTypically produced light blue-green strains with morphology similar to C. krusei, but some (4) produced small to medium smooth, convex, creamy 
pink colonies.Page 2 of 5
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ulation in duplicate onto commercially prepared CHRO-
Magar Candida (CaC) plates (BD, Sparks, MD).
Inoculated CaC plates were incubated in parallel at 30°C
and 37°C. Two independent readers, blinded to species
inoculated, observed each set of plates for color and col-
ony morphology daily for 7 days. Following the initial
blinded study, select isolates were repeated in an
unblinded fashion in parallel with the control isolates for
direct comparison.
Results
Individual isolates produced the same colors at both incu-
bation temperatures. In general, these colors appeared
more intense at 37°C and intensified daily at both tem-
peratures, peaking at 72 hours. Most of the NAC (C.
famata, C. firmetaria, C. guilliermondii, C. inconspicua, C.
kefyr, C. lipolytica, C. lusitaniae, C. norvegensis, and C. par-
apsilosis) tested produced variable shades of ivory, pink,
and lavender (Table 1). C. parapsilosis isolates were the
most varied of all species tested, in both color and colony
morphology. C. kefyr commonly produced large colonies
with centers that deepened to a brownish color with dura-
tion of incubation. C. firmetaria and C. inconspicua isolates
produced large flat colonies. Most of the C. firmetaria and
all of the C. inconspicua were pink with pale borders and
rough in texture, indistinguishable from the color and
morphology of C. krusei. C. rugosa most commonly
(eleven of 15 isolates) produced light blue-green colonies
with pale borders, similar in morphology (large, flat) to C.
krusei. The minority of isolates grew as small to medium
pink colonies not distinguishable from many other spe-
cies.
C. glabrata was readily identifiable using CaC, producing
small, convex, dark pink to violet colonies. Peak color
intensity was noted at 72 hours when incubated at 30°C
and at 48 hours when incubated at 37°C. C. glabrata iso-
lates typically produced colonies with thin pale borders
and a deep violet pigment that diffused into the medium.
Unfortunately, neither of these features were universal.
Our readers could not distinguish the medium to dark
green colonies produced by C. dubliniensis from those of
C. albicans at either temperature or any duration, except
when directly compared to each other on repeat testing.
Discussion
Amphotericin B, fluconazole, and caspofungin are cur-
rently the three antifungal agents most commonly used to
treat candidemia and invasive candidiasis. This practice is
supported by FDA approval and the most recent Infec-
tious Diseases Society of America guidelines [19]. While
all these agents have been used effectively in clinical stud-
ies, these studies included mostly patients with C. albicans
infections; thus their efficacy against NAC is not necessar-
ily universal or well known. In vitro study has shown
decreased susceptibility to amphotericin B in isolates of C.
famata, C. guilliermondii, C. inconspicua, C. kefyr, C. krusei,
C. lusitaniae, and C. rugosa and to fluconazole in isolates
of C. famata, C. firmetaria, C. guilliermondii, C. inconspicua,
C. krusei, and C. lusitaniae [7,8]. The MICs of caspofungin
have been demonstrated to be higher in C. famata, C. guil-
liermondii, and C. parapsilosis isolates [20]. The number of
antifungal agents available continues to increase in the
setting of a shift of candidal infections to those caused by
non-albicans species. Because of this, identification to spe-
cies and increased use of susceptibility testing has become
necessary to appropriately select which agent to use [21].
CHROMagar Candida is a chromogenic medium that is
advertised as able to identify C. albicans, C. krusei, and C.
tropicalis. With the increasing incidence of human disease
being produced by the less common Candida species, we
were interested in testing the performance of this medium
with the less common agents of candidiasis. We found, as
previously reported, that most of these rarer Candida spe-
cies and C. parapsilosis produced typical convex, creamy
yeast colonies in shades of pink, lavender, and less com-
monly ivory, not distinguishable from each other (and
often not consistent between isolates of the same species).
C. parapsilosis, one of the most commonly recovered NAC,
produced the widest range of colors and morphologies,
making it impossible to identify using this medium.
Many of the rare NAC produced morphology and colors
similar to those seen with C. krusei on this medium. We
found individual isolates of C. lipolytica and C. norvegensis,
many isolates of C. firmetaria, and all tested C. inconspicua
were indistinguishable from C. krusei. Some that were dis-
tinguishable, produced similar color as that of C. krusei,
with the pale border, but with waxy colonies. Most of
these species share reduced susceptibility to fluconazole
that is common with C. krusei.
We confirmed our previous observation that C. rugosa
appears to typically produce a readily identifiable and
unique color/colony type on CaC [12,22]. Eleven of 15
isolates of this organism produced the same light blue-
green color and a colonial morphology similar to that of
C. krusei. C. rugosa has been shown in clinical reports and
by in vitro testing to be less susceptible to amphotericin B
[7,8,23]. Rapid identification of this NAC is of great
importance to allow provision of appropriate therapy to
patients.
As previously reported by our group and others, this study
did find C. glabrata to be readily distinguishable from
other species that produced pink to lavender colonies on
CaC. With the use of larger numbers of isolates, we again
noted that this species produced smaller colonies startingPage 3 of 5
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commonly with a small diffusion of dark violet pigment
into the surrounding agar and a thin pale border [12,22].
This was most apparent after prolonged incubation (72
hours) at the lower temperature suggested by the manu-
facturer (30°C), or after 48 hours when incubated at
37°C.
Our readers could not distinguish C. dubliniensis from C.
albicans when observed in a blinded fashion. The isolates
we tested were somewhat darker, especially at the higher
incubation temperature, but this was only obvious when
CaC culture was performed in parallel to C. albicans con-
trols. The report by Kirkpatrick et al. [9] that made the ini-
tial observation that C. dubliniensis produce darker green
colonies with CaC did this with primary isolation of clin-
ical materials onto the medium. Our isolates were not
from primary samples and thus may have been affected by
storage conditions and repeated subculturing. Odds and
Davidson reported that they could differentiate C. dub-
liniensis from C. albicans using stored isolates, but this was
best shown after 72 hours of incubation at 37°C [10].
Conclusion
In our hands CHROMagar Candida shows good potential
as a screening medium to rapidly identify potentially
azole-resistant as well as amphotericin B-resistant species,
including C. krusei, C. glabrata. C. rugosa, and C. incon-
spicua. Identification of C. dubliniensis appears to have
some limitations based on our study, but CaC appears
(from other studies) to also hold this potential when used
as a primary medium. We would suggest inclusion of a C.
albicans control plate if this medium is used as a primary
fungal recovery medium to help increase the presumptive
identification of C. dubliniensis. Combined with confirma-
tion of speciation by standard methods and knowledge of
the local antifungal susceptibility patterns of these spe-
cies, CaC may be a useful adjunctive medium for use in
the clinical laboratory.
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